Recombinant Human Anti-EGFR Antibody (Matuzumab) (CAT#: PABX-051)

Anti-EGFR antibody is a Chimeric antibody (mouse/human) of IgG class that binds to an EGFR.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA
WB

Figure 1 Effects of cetuximab or matuzumab alone on EGF-induced phosphorylation of (A) EGFR (Tyr845, Tyr992, Tyr1045 eTyr1068).

Figure 1 Effects of cetuximab or matuzumab alone on EGF-induced phosphorylation of (A) EGFR (Tyr845, Tyr992, Tyr1045 eTyr1068).

Effects of cetuximab or matuzumab alone on EGF-induced phosphorylation of (A) EGFR (Tyr845, Tyr992, Tyr1045 eTyr1068 on A431 cells by Western Blotting as described undermaterial and methods.

Meira, D. D., Nóbrega, I., de Almeida, V. H., Mororó, J. S., Cardoso, A. M., Silva, R. L., ... & Ferreira, C. G. (2009). Different antiproliferative effects of matuzumab and cetuximab in A431 cells are associated with persistent activity of the MAPK pathway. European journal of cancer, 45(7), 1265-1273.

FC

Figure 2 Matuzumab fails to induce chemo/radio sensitization of A431, Caski and C33A gynecological cancer cell lines.

Figure 2 Matuzumab fails to induce chemo/radio sensitization of A431, Caski and C33A gynecological cancer cell lines.

(A) EGFR expression detected by Matuzumab on FACS analysis of A431, Caski and C33A cells, Student's t test * P < 0.05, when compared to controls.

Meira, D. D., Almeida, V. H., Mororó, J. S., Caetano, M. S., Nóbrega, I. P., Batista, D., ... & Ferreira, C. G. (2011). Efficient Blockade of Akt signaling is a determinant factor to overcome resistance to Matuzumab. Molecular cancer, 10(1), 151.

ELISA

Figure 3 Binding of mAbs cetuximab and matuzumab to peptide arrays.

Figure 3 Binding of mAbs cetuximab and matuzumab to peptide arrays.

Binding of mAbs cetuximab and matuzumab to synthetic peptides VLPKTLCGGGS (left) and ACKYPLGHQCGGGS(right) was measured by ELISA by adding serial dilutions of cetuximab, matuzumab or anti-ErbB2 mAb trastuzumab as control totriplicate samples of immobilized peptides (c). Data are represented as mean±s.d.

Hartmann, C., Müller, N., Blaukat, A., Koch, J., Benhar, I., & Wels, W. S. (2010). Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response. Oncogene, 29(32), 4517.

IF

Figure 4 Anti-peptide antibodies bind to the surface of EGFR-expressing cells.

Figure 4 Anti-peptide antibodies bind to the surface of EGFR-expressing cells.

Renca-lacZ/EGFR cells were incubated with rabbitanti-KTL peptide antibodies generated by immunization with synthetic peptide VLPKTLCGGGS (a). Control cells were incubatedwith matuzumab, pre-immune rabbit serum or anti-peptide antibodies pretreated with a 40-fold molar excess of specific peptide asindicated. Bound antibodies were detected with FITC-conjugated anti-rabbit IgG (anti-peptide antibodies) or anti-human IgG(matuzumab). Cell bodies were visualized by staining with an excess of propidium iodide (PI).

Hartmann, C., Müller, N., Blaukat, A., Koch, J., Benhar, I., & Wels, W. S. (2010). Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response. Oncogene, 29(32), 4517.

Inhib

Figure 5 Anti-peptide antibodies block ligand binding to EGFR and inhibit the growth of EGFR-overexpressing tumor cells.

Figure 5 Anti-peptide antibodies block ligand binding to EGFR and inhibit the growth of EGFR-overexpressing tumor cells.

Inhibitionof tumor cell growth by anti-peptide antibodies (c). Triplicate samples of A431 and MDA-MB468 cells were incubated with 50 mg/ml ofanti-KTL or anti-YPLG peptide antibodies, or matuzumab, trastuzumab or pre-immune serum as indicated. The relative number ofviable cells in comparison to PBS-treated controls was determined after 70 h in MTT cell viability assays. Representative data from oneof two independent experiments are shown. Statistically significant differences between PBS-treated group and groups treated withantibodies are indicated. ***Po0.001; **Po0.01; NS, P40.05. Data are represented as mean±s.d.

Hartmann, C., Müller, N., Blaukat, A., Koch, J., Benhar, I., & Wels, W. S. (2010). Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response. Oncogene, 29(32), 4517.


Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Mouse
  • Derivation
  • Human
  • Type
  • IgG
  • Specificity
  • Tested positive against native Human EGFR
  • Species Reactivity
  • Human
  • Clone
  • Matuzumab
  • Applications
  • WB, Neut, FuncS, FC, ELISA, IF, Inhib

Product Property

  • Purity
  • >95% by SDS-PAGE and HPLC analysis
  • Storage
  • Store the antibody (in aliquots) at -20°C. Avoid repeated freezing and thawing of samples.

Applications

  • Application Notes
  • The EGFR antibody has been reported in applications of Western Blot, Neutralization, Functional Assay, Flow Cytometry, Enzyme-linked Immunosorbent Assay, Immunofluorescence, Inhibition.
    For Flow Cytometry: Cells were incubated either with a murine anti-EGFR Mab (0.1 μg/uL) or matuzumab (0.1 μg/uL) for 1 h on ice. After washing, secondary antibodies were added and samples were analyzed on a FCcalibur using CELLQuest software.

Target

  • Alternative Names
  • EGFR; epidermal growth factor receptor; ERBB; HER1; mENA; ERBB1; PIG61; NISBD2; proto-oncogene c-ErbB-1; cell growth inhibiting protein 40; erb-b2 receptor tyrosine kinase 1; cell proliferation-inducing protein 61; receptor tyrosine-protein kinase erbB-1; avian erythroblastic leukemia viral (v-erb-b) oncogene homolog; mAb806; LICR 806; ABT-806; ch806

Related Resources

  • Biosimilar Overview
  • Related Diseases
  • Related Signaling Pathways
Please refer to Matuzumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Matuzumab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Clone Matuzumab"

See other products for "EGFR"

Chimeric Antibody

CAT Product Name Application Type
TAB-750 Anti-EGFR/HER1 Recombinant Antibody (Futuximab/Zatuximab) Neut, ELISA, IF, IP, FuncS, FC, WB IgG1 - kappa
TAB-003 Anti-Human EGFR Recombinant Antibody (Cetuximab) IF, IP, Neut, FuncS, ELISA, FC, ICC IgG1 - kappa
TAB-0225CL-F(E) Human Anti-EGFR Recombinant Antibody; Fab Fragment (TAB-0225CL-F(E)) Block, Inhib, FuncS, Apop, In vivo Chimeric (Mouse/Human) Fab
TAB-272MZ-F(E) Human Anti-EGFR Recombinant Antibody; Fab Fragment (TAB-272MZ-F(E)) FuncS Chimeric (mouse/human) Fab
TAB-308MZ-F(E) Human Anti-EGFR Recombinant Antibody; Fab Fragment (TAB-308MZ-F(E)) ELISA, FC Chimeric antibody (mouse/human)

Human Antibody

CAT Product Name Application Type
TAB-040 Anti-Human EGFR Recombinant Antibody (Zalutumumab) ELISA, FC, IP, FuncS, IF, Neut, ICC IgG1 - kappa
TAB-119 Anti-Human EGFR Recombinant Antibody (Necitumumab) FC, IP, ELISA, Neut, FuncS, IF, WB IgG1 - kappa
TAB-313MZ-F(E) Anti-Human EGFR Recombinant Antibody Fab Fragment (EG-19-11) ELISA, FC Human antibody
TAB-314MZ-F(E) Anti-Human EGFR Recombinant Antibody Fab Fragment (EG-26-11) ELISA, FC Human antibody
PABX-053 Recombinant Human Anti-EGFR Antibody (DL11) WB, ELISA, FuncS IgG

Fc Glycosylation

High-mannose Glycoform

CAT Product Name Application Type
Gly-055LC-1 Recombinant Anti-Human EGFR Antibody (Fc glycosylation/High-mannose glycosylated) ELISA Chimeric antibody (mouse/human)

Deglycosylated Antibody (Non-glycosylated IgGs)

CAT Product Name Application Type
Gly-167LC Recombinant Anti-Human EGFR Antibody (Non-glycosylated) ELISA Human antibody

Chicken IgY Antibody

CAT Product Name Application Type
BRD-0183MZ Chicken Anti-EGFR Polyclonal IgY WB Chicken antibody
BRD-0668MZ Chicken Anti-EGFR Polyclonal IgY WB Chicken antibody

Neutralizing Antibody

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-165 Afuco™ Anti-EGFR ADCC Recombinant Antibody (Matuzumab), ADCC Enhanced Neut, ELISA, IF, IP, FuncS, FC ADCC enhanced antibody
AFC-TAB-464CQ Afuco™ Anti-EGFR ADCC Recombinant Antibody (Tomuzotuximab), ADCC Enhanced ELISA, IHC, FC, IP, IF, FuncS ADCC enhanced antibody
AFC-TAB-003 Afuco™ Anti-EGFR ADCC Recombinant Antibody (Cetuximab), ADCC Enhanced IF, IP, Neut, FuncS, ELISA, FC ADCC enhanced antibody
AFC-TAB-040 Afuco™ Anti-EGFR ADCC Recombinant Antibody (Zalutumumab), ADCC Enhanced ELISA, FC, IP, FuncS, IF, Neut ADCC enhanced antibody
AFC-TAB-119 Afuco™ Anti-EGFR ADCC Recombinant Antibody (Necitumumab), ADCC Enhanced FC, IP, ELISA, Neut, FuncS, IF ADCC enhanced antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for PABX-051. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare